A Randomized, 32 Week Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy and Safety of Initiating Treatment With Combination (Aliskiren/Amlodipine) Therapy in Comparison With the Sequential Add-on Treatment Strategies in Patients With Essential Hypertension.

Trial Profile

A Randomized, 32 Week Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy and Safety of Initiating Treatment With Combination (Aliskiren/Amlodipine) Therapy in Comparison With the Sequential Add-on Treatment Strategies in Patients With Essential Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jan 2015

At a glance

  • Drugs Aliskiren/amlodipine (Primary) ; Aliskiren; Amlodipine
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms ACCELERATE
  • Sponsors Novartis
  • Most Recent Events

    • 24 May 2011 Results presented at the 26th Annual Scientific Meeting of the American Society of Hypertension.
    • 16 May 2011 Trial phase changed from III to IV as reported by ClinicalTrials.gov.
    • 13 Jan 2011 Results were published in the Lancet [online].
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top